Formulary Chapter 5: Infections - Full Chapter
|
05.01.13 |
Urinary-tract infections |
|
|
Methenamine hippurate tabs
|
Formulary
|
  Can be considered third line use for prevention of recurrent UTI in non-pregnant women (if no renal or hepatic impairment) after simple measures for symptom relief and stand-by or post-coital antibiotics have been ineffective.
Refer to local antimicrobial guidance
|
Uro-Vaxom capsules (lyophilized bacterial extract from 18 strain of E-coli)
|
Unlicensed
|
  
Approved for the prophylaxis of uncomplicated recurrent UTI
Dose = 6 mg daily for 3 months
Restricted to:
- Failure of least one 3 month course of oral prophylactic antimicrobials
- Failure of at least one 3 month course of methenamine hippurate (if suitable)
- More than two urinary tract infections in the past six months
- Culture proven growth within the last three months of Escherichia coli
|
Key |
|
|
Cytotoxic Drug
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
Status |
Description |

|
Specialist or hospital prescribing only.
The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital.
In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.
|

|
Treatment can be initiated in primary care after a recommendation from an appropriate specialist |

|
Specialist initiation followed by maintenance prescribing in primary care |

|
Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation |

|
Specialist and non-specialist initiation |

|
Not recommended for prescribing |
|
|